ArticleJournal of neurosurgery. Case lessons2026
Sporadic sarcoma arising from a previously resected benign vestibular schwannoma without neurofibromatosis or radiosurgery: illustrative case.
Article in Journal of neurosurgery. Case lessons, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundVestibular schwannomas (VSs) are common benign tumors of the cerebellopontine angle, often treated with surgery or stereotactic radiosurgery to preserve nerve function. Malignant transformation of VS (MTVS) is exceedingly rare and has been primarily associated with neurofibromatosis type 1 (NF1), neurofibromatosis type 2-related schwannomatosis (NF2-SWN), or prior radiation exposure. However, cases of MTVS occurring without these risk factors are rare and remain poorly understood. OBSERVATIONS: A 58-year-old woman without neurofibromatosis underwent subtotal VS resection in 2019, with stable residual tumor and no adjuvant treatment. In 2023, she developed acute neurological decline, and imaging suggested malignant transformation or a new tumor. Surgery confirmed a high-grade neoplasm, likely leiomyosarcoma or malignant peripheral nerve sheath tumor, with genetic analysis revealing no NF1 or NF2-SWN mutations. She received adjuvant stereotactic radiation therapy, and at the 3-month follow-up, imaging showed stable residual disease. However, she continued to experience persistent neurological deficits, including facial weakness, ataxia, and intention tremor, with a Karnofsky Performance Scale score of 60%. LESSONS: MTVS is extremely rare without neurofibromatosis or prior radiation therapy, potentially driven by surgical inflammation or unidentified genetic alterations. While increased surveillance after subtotal resection may be considered, more research is needed to identify predictive markers and guide clinical management. https://thejns.org/doi/10.3171/CASE251003.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.